Lung Cancer

Phase II trial results of HGS-ETR1 in lung cancer patients reported

Published in Cancer Weekly, August 2nd, 2005

Human Genome Sciences, Inc., (HGSI) announced that the results of a phase II clinical trial demonstrate that HGS-ETR1 (mapatumumab) is well tolerated and can be administered safely in patients with advanced non-small cell lung cancer (NSCLC).

Stable disease was observed in a number of patients.

Data on 32 patients were presented in Barcelona, Spain, at the 11th World Conference on Lung Cancer in a poster entitled "Results of a phase II Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Recurrent Non-Small Cell Lung Cancer."

The trial, which was conducted in the United States, was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-08-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry